KLOW Side Effects: Component by Component, and What to Report

The most frequent report by a wide margin, as with every subcutaneous peptide. A small red, itchy or firm area that fades within a day or two is expected. Copper compounds are mildly irritant to skin, so a small red spot after a GHK-Cu-containing injection is almost always irritation rather than allergy. Rotating between abdomen and thigh, letting the alcohol dry and a fresh syringe every time reduce it. Technique is in how to inject peptides safely.

What needs attention is direction of travel. A site that is larger, hotter or more painful at 48 hours than at 24 hours can be infection rather than irritation and needs a same-day message.

The KLOW solution is blue because of the copper in GHK-Cu, and a faint blue-green mark at the site is copper that has not yet dispersed. People who have not been told about it assume it is bruising. It clears on its own. Why is GHK-Cu blue explains what a normal vial looks like and when one looks wrong.

Early nausea and light-headedness are reported by some people on KLOW. A metallic taste is reported occasionally with GHK-Cu, is the kind of symptom copper produces at higher exposure, and is more often reported by people using more than one copper-containing product. A brief warm or flushed feeling after a dose is described with TB-500 and BPC-157. Anyone on blood-pressure medication should say so at intake. These are reasons to message your care team, not to push through and not to change the dose yourself.

Some patients describe feeling tired, flat or foggy during the first one to two weeks, which is a prescriber-described pattern for TB-500 and BPC-157 rather than a trial finding. It usually settles without any change. Fatigue that persists beyond a few weeks has many possible causes and should be reported rather than put down to the peptide.

GHK-Cu delivers copper. In a person with normal copper handling, the copper per dose at the printed directions is a small fraction of what an ordinary diet supplies, and a working liver excretes it. The risk lives in specific people:

• Wilson's disease or another copper-metabolism disorder. The body cannot excrete copper normally. This rules KLOW out.
• Significant liver disease. The liver is the body's copper exit route, so impaired liver function narrows the margin.
• High-dose zinc. Zinc and copper compete, and your physician cannot judge your copper balance without knowing your zinc dose. Do not change your zinc on your own in either direction.
• A second GHK-Cu product. Every GHK-Cu blend carries a full GHK-Cu dose, so KLOW alongside standalone GHK-Cu, GLOW, RADIANCE, REVIVE, ETERNAL or EUPHORIA doubles the copper.

The symptoms copper excess would produce are persistent nausea and vomiting, abdominal pain, yellowing of the skin or eyes, and new confusion. That pattern is not reported at prescribed doses in people with normal copper handling, but it is worth knowing. The full copper picture is in is GHK-Cu safe.

BPC-157, TB-500 and GHK-Cu are all described in animal and cell research as supporting new blood-vessel growth, which a healing tissue needs and a tumour also uses. Research on the parent protein of TB-500, thymosin beta-4, shows many tumours express it at high levels. No study shows that any of the four causes or accelerates cancer, and no study shows that they do not. Active or recent cancer is a reason not to prescribe KLOW; a cancer in remission is a conversation that includes your oncologist. See can peptides cause cancer.

In the FDA's review of BPC-157's 28-day animal studies, clotting time moved in opposite directions in rats and dogs, at doses far above anything prescribed, and no human clotting data exist. TB-500's vascular mechanisms point the same way. In practice, anticoagulant or antiplatelet therapy goes on the intake, and unexplained bleeding or bruising away from the injection site is a reason to stop and call.

The FDA's central stated concern for injected BPC-157 and TB-500 is immunogenicity: the capacity of an injected peptide to provoke an immune response, made more likely by aggregation and synthesis impurities. It is a theoretical concern rather than a report of reactions occurring, and it is the strongest argument for a licensed pharmacy that tests identity, purity and sterility. Lot test results for Pepti's pharmacies are at /quality/lab-results.

KPV is the fragment of alpha-MSH that keeps the anti-inflammatory signalling and drops the pigmentation effect, so darkening is not expected. One report in the FDA's adverse-event database described diffuse skin darkening and gum darkening in a person using a research-use-only vial labelled as BPC-157 plus TB-500, recurring when they restarted and resolving when they stopped; the agency could not tell whether either peptide, a contaminant or an impurity was responsible, and it has not been reported with pharmacy-compounded product. Any change in skin colour on treatment is a reason to stop and tell your care team.